First-line treatment of advanced ovarian cancer: current research and perspectives

@article{Marchetti2010FirstlineTO,
  title={First-line treatment of advanced ovarian cancer: current research and perspectives},
  author={Claudia Marchetti and Carmela Pisano and Gaetano Facchini and Giovanni Salvatore Bruni and Francescapaola Magazzino and Simona Losito and Sandro Pignata},
  journal={Expert Review of Anticancer Therapy},
  year={2010},
  volume={10},
  pages={47 - 60}
}
Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival. To date, intensive surgical staging and cytoreduction, followed by primary chemotherapy with the carboplatin–paclitaxel regimen, are considered the gold standard for the management of this disease. Nevertheless, despite good initial response to systemic therapy after optimal debulking surgery, the… Expand
Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer
TLDR
There is a need to identify novel agents and personalized strategies that will improve clinical outcomes in this disease and a better understanding of the molecular changes in the pathogenesis of ovarian cancer will pave the way for more effective therapeutic options. Expand
An overview of early investigational therapies for chemoresistant ovarian cancer
TLDR
An overview of early investigational drugs for the treatment of ‘platinum-resistant’ EOC is provided, based on English peer-reviewed articles located on MEDLINE and related abstracts presented at major international meetings. Expand
Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status.
  • P. Bhatt, I. Vhora, +4 authors R. Mashru
  • Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2016
TLDR
The fundamentals in development of antibody based therapeutics and multitude ways of clinical applications in diagnosis and treatment of ovarian cancer are explored, with an overview to unmet challenges so as to develop better immunotherapeutics in future. Expand
Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.
TLDR
The objective of this article is to highlight the most frequently encountered and most limiting toxicities of current standard therapies for epithelial ovarian cancer. Expand
Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients.
  • J. Mayba, P. Lambert, +5 authors M. Nachtigal
  • Medicine
  • Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2018
TLDR
It was found that patients with shorter diagnostic intervals, more advanced age, and unclassified epithelial histotype were more likely to receive neoadjuvant chemotherapy and there is treatment selection bias for sicker patients being treated with NAC. Expand
Multiple lines of chemotherapy for patients with high‐grade ovarian cancer: Predictors for response and effect on survival
TLDR
Time interval from the previous line of chemotherapy is the major clinical factor that predicts beneficial effect of another line of treatment in patients with ovarian cancer. Expand
Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.
TLDR
Several membrane receptors associated with pivotal cellular processes and often aberrantly overexpressed in ovarian cancer cells have emerged as potential targets for receptor-mediated therapeutic strategies including specific agents and multifunctional delivery systems based on ligand-receptor binding. Expand
Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses
TLDR
Recent advances in adenovirus-based oncolytic therapies targeting ovarian cancer and recent advances in mapping immune responses to on colytic virus therapies in ovarian cancer are covered. Expand
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
TLDR
The rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients are described. Expand
Splenectomy during cytoreductive surgery in epithelial ovarian cancer
TLDR
Most patients achieved optimal surgery, and thus their overall survival and postsplenectomy survival rates were longer and the prognosis of patients was closely related to chemosensitivity and presence of residual tumors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 117 REFERENCES
Pharmaceutical Management of Ovarian Cancer
TLDR
Reasonable goals of therapy in women with recurrent or resistant ovarian cancer are to improve overall survival, reduce the severity (and delay the occurrence of symptoms) of symptoms and optimize overall quality of life. Expand
New options for the treatment of advanced ovarian cancer.
TLDR
Chemotherapy drugs for advanced ovarian cancer with novel mechanisms of action include topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, which was recently shown to be effective in platinum-refractory or -resistant patients, with response rates ranging from 14% to 23%. Expand
New options for the treatment of advanced ovarian cancer.
TLDR
Chemotherapy drugs for advanced ovarian cancer with novel mechanisms of action include topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, which is shown to be effective in platinum-refractory or -resistant patients, with response rates ranging from 14% to 23%. Expand
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
TLDR
The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer. Expand
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
  • M. Bookman, M. Brady, +13 authors L. M. Roth
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction as well as survival analyses of groups defined by size of residual disease. Expand
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
TLDR
The three-drug combination ET-Carbo, given according to the outlined dose and schedule, should be considered for further phase III evaluation and preliminary analysis indicated promising activity against ovarian cancer. Expand
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau
TLDR
Addition of epirubicin to TC did not improve survival or time to treatment failure in patients with advanced epithelial ovarian cancer; therefore, it cannot be recommended for clinical use in this population. Expand
Chemotherapy in advanced ovarian cancer.
TLDR
The available evidence, although not conclusive, suggests that platinum-based chemotherapy is better than non-platinum therapy and there is some evidence that combination therapy improves survival compared with platinum alone. Expand
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
TLDR
Bvacizumab has single-agent activity in patients with platinum-resistant EOC or PSC and a higher than expected incidence of GIP was noted in these heavily pretreated patients. Expand
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.
TLDR
PLD plus carboplatin is highly effective, prolongs OS, and is well tolerated in women with AOC in late relapse previously treated with both platinum and taxanes. Expand
...
1
2
3
4
5
...